Xencor Shares Jump 20% to 52-Week High as Kidney Cancer Drug XmAb819 Shows 45.5% Response Rate in Early Trial
Xencor Inc. shares rose 20% to a 52-week high after presenting early trial data showing its kidney cancer drug XmAb819 shrank tumors in 45.5% of patients. The stock reached $30.12, with a market value of $2.25 billion. The company plans to discuss accelerated approval with the FDA in 2027. Analysts' price targets were exceeded, with Wedbush at $30 and Truist at $29.
How this was made
The 30-second read
Why it matters
The disclosed efficacy and dose-selection support for Phase 3, plus plans to discuss an accelerated approval pathway with the FDA in early 2027, are likely to drive incremental repricing of clinical success odds.
Market read
Traders get a same-week catalyst from ESMO-linked clinical data, including quantified ORR and explicit Phase 3 dose designation language.
What to watch
The article does not provide safety/tolerability details, durability beyond six months, or biomarker response rates, which can materially change the probability-weighted outlook for accelerated approval and Phase 3 success.
Background
XmAb819 is a bispecific antibody targeting ENPP3 on tumor cells and CD3 on immune T cells, being developed for advanced clear cell renal cell carcinoma.
Ticker impact
Xencor shares jumped after early Phase 1 data for XmAb819 showed a 45.5% confirmed objective response rate in 11 evaluable patients and supported a proposed Phase 3 dose.
Likely near-term upside pressure as traders price higher probability of successful Phase 3 and potential accelerated-approval discussions.
The article cites specific efficacy metrics (45.5% ORR, 82% progression-free at six months) and states management will use the 400 mcg/kg dose for Phase 3, which is a direct catalyst for sentiment and valuation, despite the small cohort.
Market effects
Reinforces investor appetite for ENPP3-targeting bispecific T-cell engagers in solid tumors, potentially lifting sentiment across the solid-tumor bispecific peer group.
Primarily US Nasdaq biotech sentiment; broader markets were mixed ahead of the Fed decision.
ESMO conference data flow can shift global biotech risk appetite, especially for oncology immunotherapy platforms.
Counterpoint
Phase 1 results on only 11 evaluable patients may not translate to Phase 3, so the stock could retrace if later cohorts show lower response rates or safety issues.
Key entities
- companyXencor Inc.
Nasdaq-listed biotech whose XmAb819 early Phase 1 data triggered a sharp share move.
- drugXmAb819
ENPP3 x CD3 bispecific antibody in Phase 1 for advanced clear cell renal cell carcinoma.
- regulatorU.S. Food and Drug Administration (FDA)
Planned discussion in early 2027 about a possible accelerated approval pathway.
- conferenceEuropean Society for Medical Oncology (ESMO) Congress
Venue where updated Phase 1 results were presented before the Monday open.
